Article Index

Article Index by Subject Category JMCP—July/August 1995 through June 2007 Editor's note: This index is intended to categorize the entire 13-year archive of JMCP articles, editorials, commentaries, letters, and supplements to inform about what is already known in these areas of managed care research. This index complements the word-search capability at “Search JMCP” available at www.amcp.org. Adherence, Compliance, and Persistence • Patient adherence with hypertension medication (letter). 2004;10(1):90-91. • Measuring adherence to antihypertensive drug therapy (letter). 2004;10(1):88-89. • Hypertension, prescription drug copayments and drug therapy adherence. 2003;9(5):454-56. • Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. 2003;9(5):424-29. • Measuring adherence and persistence in drug therapy. 2002; 8(3):204-46. • Patient adherence with HMG reductase inhibitor therapy among users of two types of prescription services. 2002; 8(3):186-91. • Adherence, compliance, and persistence in drug therapy. 2002; 8(3):177-78. • A team approach to address antiretroviral therapy adherence barriers in a managed care organization. 2001;7(3):214-18. • The Michigan pharmacists association patient persistency project. 2001;7(1):50-55. • Evaluating medication adherence: which measure is right for your program? 2000;6(6):499-504. • Unclaimed prescriptions requisitioned through provider order entry. 1999;5(6):498-502. • Predicting adherence to prescription medication purchase among HMO enrollees with diabetes. 1999;5(4):336-41. • Analyzing variations in medication compliance related to individual drug, drug class, and prescribing physician. 1999; 5(1):47-51. • A study on the characteristics of prescription transmittal processes and the effect of a patient prescription reminder system on patient compliance. 1998;4(2):174-78. • “Abandoned prescriptions”: a quantitative assessment of their cause. 1995;1(3):193-99. Adverse Drug Events • Preventable drug-related morbidity (PDRM) (editorial). 2003; 9(2):178. • Indicators of preventable drug-related morbidity in older adults. 2. Use within a managed care organization. 2003;9(2):134-41. • Medical errors, adverse medical events, and PDRM. 2002;8(5): 400. • Preventable drug-related morbidity indicators in the U.S. and U.K. 2002;8(5):372-77. • Preventable drug-related morbidity in older adults. 1. Indicator development. 2002;8(5):365-71. • Evaluation of resources used to treat adverse events of selective serotonin reuptake inhibitor use. 2001;7(5):402-06. • Adverse drug events: a plea for reporting and new rules to ease the burden. 1998;4(4):364. Behavioral Health • Issues and trends in behavioral health and managed care. 2000;6(1):11, 12, 15-16. Biotechnology • Biotechnology and managed care. 2000;6(5):410-14. • Biotechnology as a pharmacy specialty. 1998;4(5):465, 468-70. Capitation and Risk-Financing Methods • Contractual arrangements between HMOs and medical groups to manage drug costs (editorial). 2003;9(6):572. • Financial risk relationships and adoption of management strategies in physician groups for self-administered injectable drugs. 2003;9(6):523-33. • Demographics and the cost of pharmaceuticals in a private third-party prescription program. 2000;6(5):395-402, 407-09. • Challenges to methods used in studying capitation reimbursement (letter). 2000;6(1):8. • The impact of pharmaceutical capitation to primary medical groups on the health care expenditures of Medicare HMO enrollees. 1999;5(5):414-19. • Managing pharmacy risk in physician groups. 1999;5(5):382-84. Clinical Pharmacy—Patient Consultation • Pharmacists should assume a larger role in overcoming the racial/ethnic barriers to breast cancer screening (letter). 2006;12(5):406-07. • Factors affecting pharmacist consultation services in a university health insurance plan. 2002;8(1):32-40. • Providing patient-focused care within a managed care and pharmaceutical care environment: a person/situation interactionist model for community practitioners. 2000;6(3):233-39. • Counseling: where does the profession stand? 1998;4(1):78. Clinical Pharmacy—Payment for Services • Disease management, pay-for-performance, and clinical pharmacist interventions in diabetes care (editorial). 2003;9(6):574. • Outcomes-based pharmacist reimbursement: reimbursing pharmacists for cognitive services. 2002;8(5):383-91. • Reimbursement for pharmacy cognitive services: pharmacists’ assessment. 1999;5(5):420-424. • Cost-benefit analysis of pharmaceutical care in a Medicaid population—from a budgetary perspective. 1998;4(3):303-08. • Reimbursement for pharmacy cognitive services: insurance company assessment. 1997;3(1):46-48, 50-51. • Mississippi Medicaid waiver breaks new ground for pharmacists. 1996;2(6):564, 566. • Community-based pharmacy: partnering with managed care to provide value-added services. 1996;2(5):483, 487-88. www.amcp.org Vol. 13, No. 5 June 2007 JMCP Journal of Managed Care Pharmacy 431 Article Index Clinical Pharmacy Interventions— Quality, Service, and Cost Outcomes • Medication therapy management versus drug regimen review (commentary). 2007;13(1):68-69. • Adherence to clinical practice guidelines for 7 chronic conditions in long-term-care patients who received pharmacist disease management services versus traditional drug regimen review. 2007;13(1):28-36. • Experience with a clinical decision support system in community pharmacies to recommend narrow-spectrum antimicrobials, nonantimicrobial prescriptions, and OTC products to decrease broad-spectrum antimicrobial use. 2006;12(5):390-97. • Impact of a clinical pharmacy consult service on guideline adherence and management of gabapentin for neuropathic pain. 2006;12(1):61-69. • Assessment of patient satisfaction with telephone and mail interventions provided by a clinical pharmacy cardiac risk reduction service. 2005;11(5):403-09. • The PRICE clinic for low-income elderly: a managed care model for implementing pharmacist-directed services. 2005;11(4):333-41. • Assessment of the effects of a community pharmacy women’s health education program on management of menopause survey scores. 2004;10(5):442-48. • Clinical pharmacist intervention in a primary care medical group reduces financial losses (editorial). 2004;10(4):355. • Impact on drug costs and utilization of a clinical pharmacist in a multisite primary care medical group. 2004;10(4):345-54. • Clinical pharmacist interventions to bridge the quality chasm and methods necessary to hold quality improvement gains (editorial). 2004;10(2):167-68. • Cost analysis of a managed care decentralized outpatient pharmacy anticoagulation service. 2004;10(2):159-65. • Assessment of clinical pharmacist management of lipid-lowering therapy in a primary care setting. 2003;9(3):269-73. • A pharmacist-based screening program of octogenarians starting new medications. 2003;9(1):13-18. • Crossing the quality chasm—pharmacist prescribing, nontraditional intervent (...truncated)